JP4969016B2 - 抗エストロゲン剤とファルネシルプロテイントランスフェラーゼ阻害剤の組み合わせ物 - Google Patents

抗エストロゲン剤とファルネシルプロテイントランスフェラーゼ阻害剤の組み合わせ物 Download PDF

Info

Publication number: JP4969016B2
Authority: JP; Japan
Prior art keywords: combination; alkyl; estrogen; acid; growth
Prior art date: 2001-02-15
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

JP2002563936A

Other languages

English (en)

Japanese (ja)

Other versions

JP2004517960A (ja

Inventor

エンド，デイビツド・ウイリアム

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Janssen Pharmaceutica NV

Original Assignee

Janssen Pharmaceutica NV

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-02-15

Filing date

2002-02-06

Publication date

2012-07-04

2002-02-06 Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV

2004-06-17 Publication of JP2004517960A publication Critical patent/JP2004517960A/ja

2012-07-04 Application granted granted Critical

2012-07-04 Publication of JP4969016B2 publication Critical patent/JP4969016B2/ja

2022-02-06 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

239000000328 estrogen antagonist Substances 0.000 title claims abstract description 24
239000003528 protein farnesyltransferase inhibitor Substances 0.000 title claims abstract description 19
230000001833 anti-estrogenic effect Effects 0.000 title claims description 13
229940046836 anti-estrogen Drugs 0.000 title claims description 11
229940124226 Farnesyltransferase inhibitor Drugs 0.000 claims abstract description 12
230000004614 tumor growth Effects 0.000 claims abstract description 12
210000004881 tumor cell Anatomy 0.000 claims abstract description 10
230000002401 inhibitory effect Effects 0.000 claims abstract description 7
-1 1-methyl-1H-imidazol-5-yl Chemical group 0.000 claims description 16
206010006187 Breast cancer Diseases 0.000 claims description 10
208000026310 Breast neoplasm Diseases 0.000 claims description 10
239000008194 pharmaceutical composition Substances 0.000 claims description 10
239000002253 acid Substances 0.000 claims description 9
BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims description 5
YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims description 5
239000003937 drug carrier Substances 0.000 claims description 5
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims description 5
ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 claims description 4
229960002932 anastrozole Drugs 0.000 claims description 4
239000003886 aromatase inhibitor Substances 0.000 claims description 4
229950004203 droloxifene Drugs 0.000 claims description 4
229960000255 exemestane Drugs 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
229960004622 raloxifene Drugs 0.000 claims description 4
150000003839 salts Chemical class 0.000 claims description 4
229940095743 selective estrogen receptor modulator Drugs 0.000 claims description 4
239000000333 selective estrogen receptor modulator Substances 0.000 claims description 4
XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 claims description 4
229960005026 toremifene Drugs 0.000 claims description 4
229940102550 Estrogen receptor antagonist Drugs 0.000 claims description 3
VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical group OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims description 3
229940087861 faslodex Drugs 0.000 claims description 3
229960003881 letrozole Drugs 0.000 claims description 3
HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical group C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims description 3
238000013160 medical therapy Methods 0.000 claims description 2
QYEMNJMSULGQRD-UHFFFAOYSA-N 1-methyl-2-quinolone Chemical group C1=CC=C2C=CC(=O)N(C)C2=C1 QYEMNJMSULGQRD-UHFFFAOYSA-N 0.000 claims 1
125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 1
229940122815 Aromatase inhibitor Drugs 0.000 claims 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
206010028980 Neoplasm Diseases 0.000 abstract description 39
238000011282 treatment Methods 0.000 abstract description 17
201000011510 cancer Diseases 0.000 abstract description 11
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 42
229960001603 tamoxifen Drugs 0.000 description 20
239000001257 hydrogen Substances 0.000 description 14
229910052739 hydrogen Inorganic materials 0.000 description 14
150000002431 hydrogen Chemical class 0.000 description 13
239000000262 estrogen Substances 0.000 description 12
229940011871 estrogen Drugs 0.000 description 12
108700042226 ras Genes Proteins 0.000 description 11
239000000203 mixture Substances 0.000 description 10
210000004027 cell Anatomy 0.000 description 9
239000000243 solution Substances 0.000 description 9
241000699670 Mus sp. Species 0.000 description 8
125000001475 halogen functional group Chemical group 0.000 description 8
125000004356 hydroxy functional group Chemical group O* 0.000 description 8
238000000034 method Methods 0.000 description 8
108010014186 ras Proteins Proteins 0.000 description 8
102000016914 ras Proteins Human genes 0.000 description 8
241000699666 Mus <mouse, genus> Species 0.000 description 7
125000000217 alkyl group Chemical group 0.000 description 7
239000002552 dosage form Substances 0.000 description 7
239000008188 pellet Substances 0.000 description 7
125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 description 6
150000001875 compounds Chemical class 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
230000000694 effects Effects 0.000 description 6
230000035772 mutation Effects 0.000 description 6
231100000590 oncogenic Toxicity 0.000 description 6
230000002246 oncogenic effect Effects 0.000 description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
108700020796 Oncogene Proteins 0.000 description 5
230000002159 abnormal effect Effects 0.000 description 5
201000010099 disease Diseases 0.000 description 5
102000015694 estrogen receptors Human genes 0.000 description 5
108010038795 estrogen receptors Proteins 0.000 description 5
206010061902 Pancreatic neoplasm Diseases 0.000 description 4
230000010261 cell growth Effects 0.000 description 4
125000004093 cyano group Chemical group *C#N 0.000 description 4
230000012010 growth Effects 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
239000003112 inhibitor Substances 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
230000002062 proliferating effect Effects 0.000 description 4
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
125000006619 (C1-C6) dialkylamino group Chemical group 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
229920000858 Cyclodextrin Polymers 0.000 description 3
239000001116 FEMA 4028 Substances 0.000 description 3
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 3
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
102000043276 Oncogene Human genes 0.000 description 3
102000013275 Somatomedins Human genes 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
239000000654 additive Substances 0.000 description 3
229940046844 aromatase inhibitors Drugs 0.000 description 3
WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 3
235000011175 beta-cyclodextrine Nutrition 0.000 description 3
229960004853 betadex Drugs 0.000 description 3
239000002775 capsule Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
230000014509 gene expression Effects 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
239000007788 liquid Substances 0.000 description 3
230000003211 malignant effect Effects 0.000 description 3
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
201000002528 pancreatic cancer Diseases 0.000 description 3
208000008443 pancreatic carcinoma Diseases 0.000 description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
239000000725 suspension Substances 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 2
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
PLHJCIYEEKOWNM-UHFFFAOYSA-N 6-[amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one Chemical compound CN1C=NC=C1C(N)(C=1C=C2C(C=3C=C(Cl)C=CC=3)=CC(=O)N(C)C2=CC=1)C1=CC=C(Cl)C=C1 PLHJCIYEEKOWNM-UHFFFAOYSA-N 0.000 description 2
102000014654 Aromatase Human genes 0.000 description 2
108010078554 Aromatase Proteins 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
206010009944 Colon cancer Diseases 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
101150040459 RAS gene Proteins 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
102000004357 Transferases Human genes 0.000 description 2
108090000992 Transferases Proteins 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
230000002411 adverse Effects 0.000 description 2
125000003545 alkoxy group Chemical group 0.000 description 2
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
229910052782 aluminium Inorganic materials 0.000 description 2
125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 description 2
230000033115 angiogenesis Effects 0.000 description 2
230000000259 anti-tumor effect Effects 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
230000003305 autocrine Effects 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
230000037396 body weight Effects 0.000 description 2
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
239000000969 carrier Substances 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
210000001072 colon Anatomy 0.000 description 2
208000029742 colonic neoplasm Diseases 0.000 description 2
238000011284 combination treatment Methods 0.000 description 2
230000030944 contact inhibition Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
229960005309 estradiol Drugs 0.000 description 2
229930182833 estradiol Natural products 0.000 description 2
125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
239000011888 foil Substances 0.000 description 2
239000008103 glucose Substances 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
230000002018 overexpression Effects 0.000 description 2
239000006187 pill Substances 0.000 description 2
239000000843 powder Substances 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
239000007787 solid Substances 0.000 description 2
229960005137 succinic acid Drugs 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
230000009466 transformation Effects 0.000 description 2
230000001131 transforming effect Effects 0.000 description 2
125000004953 trihalomethyl group Chemical group 0.000 description 2
230000004565 tumor cell growth Effects 0.000 description 2
DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
VOXZDWNPVJITMN-SFFUCWETSA-N 17α-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-SFFUCWETSA-N 0.000 description 1
POYSUXIHCXBJPN-UHFFFAOYSA-N 3-Methyl-quinolin-2-ol Chemical class C1=CC=C2NC(=O)C(C)=CC2=C1 POYSUXIHCXBJPN-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
241000271566 Aves Species 0.000 description 1
208000003950 B-cell lymphoma Diseases 0.000 description 1
206010005003 Bladder cancer Diseases 0.000 description 1
206010055113 Breast cancer metastatic Diseases 0.000 description 1
208000011691 Burkitt lymphomas Diseases 0.000 description 1
125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
206010048832 Colon adenoma Diseases 0.000 description 1
208000001333 Colorectal Neoplasms Diseases 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
208000005189 Embolism Diseases 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
206010014733 Endometrial cancer Diseases 0.000 description 1
206010014759 Endometrial neoplasm Diseases 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
201000008808 Fibrosarcoma Diseases 0.000 description 1
206010016935 Follicular thyroid cancer Diseases 0.000 description 1
241000233866 Fungi Species 0.000 description 1
206010064571 Gene mutation Diseases 0.000 description 1
208000032612 Glial tumor Diseases 0.000 description 1
206010018338 Glioma Diseases 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
241000282412 Homo Species 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
206010023347 Keratoacanthoma Diseases 0.000 description 1
208000008839 Kidney Neoplasms Diseases 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241000237852 Mollusca Species 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
208000009905 Neurofibromatoses Diseases 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
206010038389 Renal cancer Diseases 0.000 description 1
108091027981 Response element Proteins 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
IWEQQRMGNVVKQW-OQKDUQJOSA-N Toremifene citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 IWEQQRMGNVVKQW-OQKDUQJOSA-N 0.000 description 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
208000009956 adenocarcinoma Diseases 0.000 description 1
230000001919 adrenal effect Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
229960004909 aminosalicylic acid Drugs 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
239000003098 androgen Substances 0.000 description 1
229940030486 androgens Drugs 0.000 description 1
AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 description 1
AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 description 1
229960005471 androstenedione Drugs 0.000 description 1
230000001028 anti-proliverative effect Effects 0.000 description 1
229940078010 arimidex Drugs 0.000 description 1
229940087620 aromasin Drugs 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
206010004398 benign neoplasm of skin Diseases 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
229940092714 benzenesulfonic acid Drugs 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000005907 cancer growth Effects 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
238000012754 cardiac puncture Methods 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000010307 cell transformation Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
230000001085 cytostatic effect Effects 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
229960003399 estrone Drugs 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
229940085363 evista Drugs 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
229940043168 fareston Drugs 0.000 description 1
230000006126 farnesylation Effects 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
229960004275 glycolic acid Drugs 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
201000005787 hematologic cancer Diseases 0.000 description 1
208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
230000000937 inactivator Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
201000010982 kidney cancer Diseases 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
229960000448 lactic acid Drugs 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
GKFPROVOIQKYTO-UZLBHIALSA-N methyl (2s)-2-[[4-[[(2r)-2-amino-3-sulfanylpropyl]amino]-2-phenylbenzoyl]amino]-4-methylsulfanylbutanoate Chemical compound CSCC[C@@H](C(=O)OC)NC(=O)C1=CC=C(NC[C@@H](N)CS)C=C1C1=CC=CC=C1 GKFPROVOIQKYTO-UZLBHIALSA-N 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
230000002297 mitogenic effect Effects 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
208000025113 myeloid leukemia Diseases 0.000 description 1
DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
201000004931 neurofibromatosis Diseases 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
229940085033 nolvadex Drugs 0.000 description 1
208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
238000011580 nude mouse model Methods 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
230000003076 paracrine Effects 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000003961 penetration enhancing agent Substances 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
235000004252 protein component Nutrition 0.000 description 1
235000018102 proteins Nutrition 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
229940107700 pyruvic acid Drugs 0.000 description 1
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
230000005855 radiation Effects 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000008844 regulatory mechanism Effects 0.000 description 1
201000009410 rhabdomyosarcoma Diseases 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000004544 spot-on Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000001384 succinic acid Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
229910052717 sulfur Chemical group 0.000 description 1
239000011593 sulfur Chemical group 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000003826 tablet Substances 0.000 description 1
230000008685 targeting Effects 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
208000001608 teratocarcinoma Diseases 0.000 description 1
229960003604 testosterone Drugs 0.000 description 1
208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
125000004951 trihalomethoxy group Chemical group 0.000 description 1
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
201000005112 urinary bladder cancer Diseases 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
WHGYBXFWUBPSRW-FEYSZYNQSA-N β-dextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)C(O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FEYSZYNQSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Diabetes (AREA)
Oncology (AREA)
Endocrinology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Detergent Compositions (AREA)

JP2002563936A 2001-02-15 2002-02-06 抗エストロゲン剤とファルネシルプロテイントランスフェラーゼ阻害剤の組み合わせ物 Expired - Lifetime JP4969016B2 (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US26883901P	2001-02-15	2001-02-15
US60/268,839		2001-02-15
PCT/EP2002/001248 WO2002064142A1 (en)	2001-02-15	2002-02-06	Farnesyl protein transferase inhibitor combinations with antiestrogen agents

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2009236573A Division JP4865027B2 (ja)	2001-02-15	2009-10-13	抗エストロゲン剤とファルネシルプロテイントランスフェラーゼ阻害剤の組み合わせ物

Publications (2)

Publication Number	Publication Date
JP2004517960A JP2004517960A (ja)	2004-06-17
JP4969016B2 true JP4969016B2 (ja)	2012-07-04

Family

ID=23024710

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
JP2002563936A Expired - Lifetime JP4969016B2 (ja)	2001-02-15	2002-02-06	抗エストロゲン剤とファルネシルプロテイントランスフェラーゼ阻害剤の組み合わせ物
JP2009236573A Expired - Lifetime JP4865027B2 (ja)	2001-02-15	2009-10-13	抗エストロゲン剤とファルネシルプロテイントランスフェラーゼ阻害剤の組み合わせ物

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
JP2009236573A Expired - Lifetime JP4865027B2 (ja)	2001-02-15	2009-10-13	抗エストロゲン剤とファルネシルプロテイントランスフェラーゼ阻害剤の組み合わせ物

Country Status (7)

Country	Link
US (4)	US20040110769A1 (de)
EP (1)	EP1365763B1 (de)
JP (2)	JP4969016B2 (de)
AT (1)	ATE415161T1 (de)
DE (1)	DE60230017D1 (de)
ES (1)	ES2318000T3 (de)
WO (1)	WO2002064142A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4969016B2 (ja) *	2001-02-15	2012-07-04	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	抗エストロゲン剤とファルネシルプロテイントランスフェラーゼ阻害剤の組み合わせ物
JPWO2004035089A1 (ja) *	2002-10-09	2006-02-09	協和醗酵工業株式会社	ホルモン依存性癌の治療剤
US7838531B2 (en) *	2002-10-18	2010-11-23	The United States Of America As Represented By The Department Of Health And Human Services	Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis
EP1552020B1 (de)	2002-10-18	2012-02-29	THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES	Lmna-gen und seine beteiligung an progeria hutchinson-gilford (hgps) und arteriosklerose
CA2544421A1 (en) *	2003-11-06	2005-05-26	Schering Corporation	Combination of a farnesyl transferase inhibitor with an antihormonal agent for the treatment of breast cancer
CA2634598A1 (en)	2005-12-23	2007-07-05	Link Medicine Corporation	Treatment of synucleinopathies
US9290476B2 (en)	2012-10-16	2016-03-22	Janssen Pharmaceutica Nv	Methylene linked quinolinyl modulators of RORγt
CN104884448A (zh)	2012-10-16	2015-09-02	詹森药业有限公司	Rorγt的杂芳基连接的喹啉基调节剂
CN105073729A (zh)	2012-10-16	2015-11-18	詹森药业有限公司	RORγt的苯基连接的喹啉基调节剂
BR112016008258A2 (pt)	2013-10-15	2017-10-10	Janssen Pharmaceutica Nv	moduladores de ror?t de quinolinila
US9403816B2 (en)	2013-10-15	2016-08-02	Janssen Pharmaceutica Nv	Phenyl linked quinolinyl modulators of RORγt
US9221804B2 (en)	2013-10-15	2015-12-29	Janssen Pharmaceutica Nv	Secondary alcohol quinolinyl modulators of RORγt
US9284308B2 (en)	2013-10-15	2016-03-15	Janssen Pharmaceutica Nv	Methylene linked quinolinyl modulators of RORγt
US9328095B2 (en)	2013-10-15	2016-05-03	Janssen Pharmaceutica Nv	Heteroaryl linked quinolinyl modulators of RORgammat
US10555941B2 (en)	2013-10-15	2020-02-11	Janssen Pharmaceutica Nv	Alkyl linked quinolinyl modulators of RORγt
BR112016008215A2 (pt)	2013-10-15	2017-09-26	Janssen Pharmaceutica Nv	moduladores de quinolinila ligados por alquila de roryt
US11311519B2 (en)	2014-05-01	2022-04-26	Eiger Biopharmaceuticals, Inc.	Treatment of hepatitis delta virus infection
PL3137078T3 (pl) *	2014-05-01	2019-08-30	Eiger Biopharmaceuticals, Inc.	Leczenie zakażenia wirusem zapalenia wątroby typu delta
US10076512B2 (en)	2014-05-01	2018-09-18	Eiger Biopharmaceuticals, Inc.	Treatment of hepatitis delta virus infection
WO2016172342A1 (en)	2015-04-21	2016-10-27	Eiger Biopharmaceuticals, Inc.	Pharmaceutical compositions comprising lonafarnib and ritonavir
SMT202100712T1 (it)	2015-08-17	2022-01-10	Kura Oncology Inc	Metodi di trattamento di pazienti di cancro con inibitori di farnesil trasferasi
TW201818965A (zh)	2016-11-03	2018-06-01	美商庫拉腫瘤技術股份有限公司	以法呢基轉移酶（ｆａｒｎｅｓｙｌｔｒａｎｓｆｅｒａｓｅ）抑制劑治療癌症病患之方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3157882B2 (ja) *	1991-11-15	2001-04-16	帝国臓器製薬株式会社	新規なベンゾチオフエン誘導体
TW349948B (en) *	1995-10-31	1999-01-11	Janssen Pharmaceutica Nv	Farnesyl transferase inhibiting 2-quinolone derivatives
SK283335B6 (sk) *	1995-12-08	2003-06-03	Janssen Pharmaceutica N. V.	(Imidazol-5-yl)metyl-2-chinolinónové deriváty, spôsob a medziprodukty na ich prípravu, ich použitie a farmaceutické kompozície na ich báze
TW591030B (en) *	1997-03-10	2004-06-11	Janssen Pharmaceutica Nv	Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
RU2205831C2 (ru) *	1997-04-25	2003-06-10	Янссен Фармацевтика Н.В.	Хиназолиноны, ингибирующие фарнезилтрансферазу
DE69840126D1 (de) *	1997-08-15	2008-11-27	Univ Duke	Verfahren zur prophylaxis oder behandlung von östrogen-abhängigen krankheiten
DK1041985T3 (da) *	1997-12-22	2006-06-19	Schering Corp	Kombination af benzocycloheptapyridinforbindelser og antineoplastiske lægemidler til behandling af profilerative sygdomme
DE19826213A1 (de) *	1998-06-09	1999-12-16	Schering Ag	Neue Antiestrogene, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
WO2000025789A1 (en) *	1998-10-29	2000-05-11	Merck & Co., Inc.	A method of treating endometriosis
ID29241A (id) *	1998-12-23	2001-08-16	Janssen Pharmaceutica Nv	Turunan-turunan kinolin teranelasi-1,2
JP5491681B2 (ja) *	2000-02-04	2014-05-14	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	乳ガンの治療のためのファルネシルタンパク質トランスフェラーゼ阻害剤
US6838467B2 (en) *	2000-02-24	2005-01-04	Janssen Pharmaceutica N. V.	Dosing regimen
US7173040B2 (en) *	2000-09-25	2007-02-06	Janssen Pharmaceutica N.V.	Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derinazoline derivatives
JP4969016B2 (ja) *	2001-02-15	2012-07-04	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	抗エストロゲン剤とファルネシルプロテイントランスフェラーゼ阻害剤の組み合わせ物

2002
- 2002-02-06 JP JP2002563936A patent/JP4969016B2/ja not_active Expired - Lifetime
- 2002-02-06 WO PCT/EP2002/001248 patent/WO2002064142A1/en not_active Ceased
- 2002-02-06 AT AT02719776T patent/ATE415161T1/de not_active IP Right Cessation
- 2002-02-06 DE DE60230017T patent/DE60230017D1/de not_active Expired - Lifetime
- 2002-02-06 US US10/468,162 patent/US20040110769A1/en not_active Abandoned
- 2002-02-06 EP EP02719776A patent/EP1365763B1/de not_active Expired - Lifetime
- 2002-02-06 ES ES02719776T patent/ES2318000T3/es not_active Expired - Lifetime
2008
- 2008-09-29 US US12/240,075 patent/US20090023776A1/en not_active Abandoned
2009
- 2009-10-13 JP JP2009236573A patent/JP4865027B2/ja not_active Expired - Lifetime
2011
- 2011-01-07 US US12/986,351 patent/US20110105557A1/en not_active Abandoned
2012
- 2012-01-04 US US13/343,125 patent/US20120108634A1/en not_active Abandoned

Also Published As

Publication number	Publication date
DE60230017D1 (de)	2009-01-08
US20110105557A1 (en)	2011-05-05
JP4865027B2 (ja)	2012-02-01
EP1365763A1 (de)	2003-12-03
JP2004517960A (ja)	2004-06-17
US20090023776A1 (en)	2009-01-22
US20040110769A1 (en)	2004-06-10
EP1365763B1 (de)	2008-11-26
ATE415161T1 (de)	2008-12-15
WO2002064142A1 (en)	2002-08-22
US20120108634A1 (en)	2012-05-03
JP2010047589A (ja)	2010-03-04
ES2318000T3 (es)	2009-05-01

Legal Events

Date	Code	Title	Description
2004-12-03	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20041202
2008-02-05	RD02	Notification of acceptance of power of attorney	Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20080202
2008-03-04	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080304
2008-05-22	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080521
2008-05-29	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080528
2008-08-26	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080825
2008-10-28	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081028
2009-01-29	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090128
2009-02-10	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090209
2009-04-25	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090424
2009-06-09	A02	Decision of refusal	Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090609
2009-10-14	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091013
2009-11-17	A911	Transfer to examiner for re-examination before appeal (zenchi)	Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20091116
2009-12-21	A912	Re-examination (zenchi) completed and case transferred to appeal board	Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20091218
2011-10-21	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111020
2011-10-26	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111025
2012-04-05	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01
2012-04-12	A61	First payment of annual fees (during grant procedure)	Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120403
2012-04-13	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20150413 Year of fee payment: 3
2012-04-13	R150	Certificate of patent or registration of utility model	Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 4969016 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150
2015-04-07	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2016-04-12	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2017-04-04	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2018-04-03	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2019-04-02	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2020-03-31	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2021-03-31	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2022-02-06	EXPY	Cancellation because of completion of term

Publication	Publication Date	Title
JP4969016B2 (ja)	2012-07-04	抗エストロゲン剤とファルネシルプロテイントランスフェラーゼ阻害剤の組み合わせ物
JP7523351B2 (ja)	2024-07-26	肥満細胞症の治療のための併用療法
Haugen et al.	2013	Evolving approaches to patients with advanced differentiated thyroid cancer
KR101673731B1 (ko)	2016-11-07	벰루페닙 및 mdm2 억제제의, 증식성 질환 치료용 복합 요법
TWI469777B (zh)	2015-01-21	與非大麻素化學治療劑組合之大麻素
JP7671327B2 (ja)	2025-05-01	消化管間質腫瘍の治療のための併用療法
US12336992B2 (en)	2025-06-24	PAC-1 combination therapy
EP1255537A2 (de)	2002-11-13	Farnesyl protein transferase inhibitoren zur behandlung von brustkrebs
Ning et al.	1999	Radiosensitization by intratumoral administration of cisplatin in a sustained-release drug delivery system
KR20230112626A (ko)	2023-07-27	아베마시클립 및 6-(2,4-디클로로페닐)-5-[4-[(3s)-1-(3-플루오로프로필)피롤리딘-3-일]옥시페닐]-8,9-디히드로-7h-벤조[7]아눌렌-2-카복실산을 포함하는 병용물
Jensen et al.	2020	EGFR blockade in GBM brain tumor stem cells synergizes with JAK2/STAT3 pathway inhibition to abrogate compensatory mechanisms in vitro and in vivo
WO2001064196A2 (en)	2001-09-07	Farnesyl protein transferase inhibitor combinations with vinca alkaloids
EP3150206A1 (de)	2017-04-05	Medizinische zusammensetzung mit pyrazin-carboxamid-verbindung als wirkstoff
US6498184B2 (en)	2002-12-24	Serotonergic compound for a method of treatment of hot flushes in post-menopausal women
US12616683B2 (en)	2026-05-05	Combination therapy for the treatment of gastrointestinal stromal tumors
TW202404592A (zh)	2024-02-01	用於治療癌症之組合療法
Jensen et al.	2020	Neuro-Oncology Advances
HK40032580B (en)	2026-04-10	Combination therapy for the treatment of gastrointestinal stromal tumors
HK40032580A (en)	2021-03-26	Combination therapy for the treatment of gastrointestinal stromal tumors